newsfilter
← Latest News
GlobeNewswire·

Aravive Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates

Reported positive data from Phase 1b trials of batiraxcept in clear cell renal cell carcinoma and pancreatic adenocarcinoma in 1Q'22; on track to report updated data in 2Q'22 Dosed first patient in Phase 2 trial of batiraxcept in ccRCC in January 2022;